The Netherlands Cancer Institute: clinical-trial pipeline
The Netherlands Cancer Institute is the sponsor of 230 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 77 are not yet finished and 1 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Trials by phase
| Phase | Trials |
|---|---|
| Not applicable | 97 |
| Phase 2 | 57 |
| Phase 3 | 24 |
| Phase 1 | 22 |
| Phase 1/2 | 18 |
| Phase 2/3 | 8 |
| Early phase 1 | 2 |
| Phase 4 | 2 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 82 |
| Unknown | 47 |
| Recruiting | 44 |
| Active, not recruiting | 26 |
| Terminated | 19 |
| Not yet recruiting | 7 |
| Withdrawn or not authorised | 4 |
| Suspended or halted | 1 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 215 |
| Nephrology and urology | 28 |
| Women's health and obstetrics | 18 |
| Gastroenterology and liver | 11 |
| Cardiovascular | 5 |
| Dermatology | 5 |
| Musculoskeletal | 5 |
| Metabolic and endocrine (diabetes, obesity) | 4 |
| Psychiatry and mental health | 3 |
| Respiratory | 3 |
| Haematology | 1 |
| Immunology and rheumatology | 1 |
Countries
| Country | Trials |
|---|---|
| Netherlands | 215 |
| France | 7 |
| United Kingdom | 6 |
| Belgium | 5 |
| Denmark | 5 |
| Sweden | 5 |
| United States | 4 |
| Australia | 3 |
| Germany | 3 |
| Spain | 3 |
| Italy | 2 |
| Austria | 1 |
| Canada | 1 |
| Finland | 1 |
| Ireland | 1 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-09-08 | New trial posted | RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT02925234 | The Drug Rediscovery Protocol (DRUP Trial) | Phase 2 | Recruiting | Netherlands |
| NCT03772028 | Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) | Phase 3 | Active, not recruiting | Germany, Denmark, France, Ireland +4 |
| NCT06012734 | LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients | Phase 1 | Recruiting | Netherlands |
| NCT06353906 | Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer | Phase 2 | Not yet recruiting | Belgium, Netherlands |
| NCT05406674 | Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemother… | Phase 2 | Active, not recruiting | Netherlands |
| NCT02931890 | Multicentric Randomised Trial for Resectable Gastric Cancer | Phase 2 | Active, not recruiting | Netherlands |
| NCT04949113 | Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma | Phase 3 | Active, not recruiting | Australia, France, Italy, Netherlands +2 |
| NCT06857773 | Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusio… | Phase 3 | Recruiting | Netherlands |
| NCT06222489 | Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT | Phase 2 | Recruiting | Netherlands |
| NCT05148546 | Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer | Phase 2 | Active, not recruiting | United Kingdom, Netherlands |
| NCT04287829 | Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients | Phase 2 | Active, not recruiting | Netherlands |
| NCT05200988 | Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC | Phase 2 | Active, not recruiting | Netherlands |
| NCT04017455 | Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN) | Phase 2 | Active, not recruiting | Netherlands |
| NCT06162559 | Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TR… | Phase 1 | Recruiting | Netherlands |
| NCT03026140 | Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer | Phase 2 | Recruiting | Netherlands |
| NCT03448835 | Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cance… | Phase 2 | Active, not recruiting | Netherlands |
| NCT01898117 | Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Trea… | Phase 2 | Active, not recruiting | Netherlands |
| NCT03815890 | Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO | Phase 2 | Recruiting | Netherlands |
| NCT04159818 | Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cance… | Phase 2 | Active, not recruiting | Netherlands |
| NCT03348150 | Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination. | Phase 3 | Active, not recruiting | Denmark, Finland, Netherlands, Sweden |
| NCT06823479 | Towards Cure Via Only Ultra-short ICB in CSCC | Phase 2 | Recruiting | Netherlands |
| NCT05700656 | Galunisertib Combined With Capecitabine in Advanced CRC With PM | Phase 1/2 | Active, not recruiting | Netherlands |
| NCT02810743 | Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer | Phase 3 | Active, not recruiting | France, Netherlands |
| NCT02499367 | Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients | Phase 2 | Active, not recruiting | Netherlands |
| NCT07486687 | Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After… | Phase 3 | Recruiting | Netherlands |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "The Netherlands Cancer Institute clinical trials: 77 open, 32 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/the-netherlands-cancer-institute/, data as of 2026-10-25.